Ira David Glick, MD Pacific Research Partners, LLC 1611 Telegraph Avenue, Suite 100 & Suite 1550 Oakland, CA 94612 CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (866) 669-0234 Fax (208) 575-3169 Email: clinicaltrials@btheodore.com AFFILIATIONS: Collaborative Neuroscience Network, LLC. 12772 Valley View Street, Suite 3 Garden Grove, CA 92845 Collaborative Neuroscience Network, LLC. 2600 Redondo Avenue, Suite 500 Long Beach, CA 90806 Collaborative Neuroscience Network, LLC. 19401 S. Vermont Avenue, Suite F-100 Torrance, CA 90502 Stanford University Medical Hospital EDUCATION: 1957 B.S., Dickinson College, Carlisle, Pennsylvania 1961 M.D., New York Medical College INTERNSHIPS AND RESIDENCIES: 1965-1966 Candidate, New York Psychoanalytic Institute, New York, NY 1961-1962 Rotating Internship, Beth Israel Hospital, New York, NY 1962-1966 Psychiatry Residency: 1962-1963 First Year Resident, Hillside Hospital, Glen Oaks, New York 1963-1964 Second Year Resident, Mt. Zion Hospital, San Francisco, CA 1964-1965 Chief Resident, Hillside Hospital 12/31/2013-1 -
LICENSURE: 1962-1993 New York State Medical License 1963 Diplomate of the National Board of Medical Examiners 1963 California State Medical License - (G 9084) 1968 Diplomate of the American Board of Psychiatry and Neurology 1980 Mental Health Administrator, Commission on Certification in Administrative Psychiatry of the American Psychiatric Association 1988-1990 Maryland Medical License (License number available on request) PROFESSIONAL EXPERIENCE: Principal Investigator, 2010- Present Pacific Research Partners, Oakland, CA Professor Emeritus, Psychiatry, June 2010 Present Director, Schizophrenia Research Clinic, 1993 June 2010 Director of Inpatient & Partial Hospitalization Services, 1993-2000 Stanford University School of Medicine & Stanford University Hospital Acting Deputy Chief of Staff and Chief of Psychiatry, 1995-1996 Veterans Administration Hospital, Palo Alto, CA Associate Medical Director, 1978-1993 Payne Whitney Clinic, Department of Psychiatry, The New York Hospital Senior Science Advisor to the Director, 1988-1990 National Institute of Mental Health, Rockville, MD Director, Inpatient Services, 1978-1988 Director, of the Family Therapy Program, 1978-1993 Director, Outpatient Department, 1990-1993 Cornell Medical Center Chief, Clinical Research Ward, 1968-1978 (Renamed the Inpatient Treatment & Research Service, 5/1/75) Director, Medical Student Education, 1975-1978 Langley Porter Neuropsychiatric Institute and Dept. of Psychiatry, School of Medicine University of California, San Francisco Service Record: Captain, Army of the United States, Chief, Psychiatry Service, 1966-1968 U.S. Army Hospital Specialized Treatment Center, Fort Gordon, Georgia 12/31/2013-2 -
PROFESSIONAL EXPERIENCE (continued): Staff Psychiatrist and Research Associate, 1965-1966 Hillside Hospital, Glen Oaks, New York INVESTIGATOR EXPERIENCE: INTEREST: Adolescent Psychiatry Anxiety Bipolar Disorder Depression Insomnia Mania Schizophrenia ADHD Alzheimer s Disease Anxiety Dementia Multiple Sclerosis Post Traumatic Stress Disorder (PTSD) Sleep Disorders CLINICAL TRIAL EXPERIENCE: Addiction A Phase III, multi center, double blind, placebo controlled, randomized withdrawal study to evaluate the maintenance and efficacy of XXX in adults aged 18-55 with moderate to severe binge eating A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doseranging Study with Follow-up Evaluating the Safety and Efficacy of XXX for Smoking Cessation in Healthy Adolescent Smokers A Phase III, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of XXX in the Treatment of Adults with Binge Eating Disorder A Phase III, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder Bipolar Disorders A Phase III, 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXX as Maintenance Treatment in Patients with Bipolar I Disorder A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX as an Adjunctive Therapy to Treatment-as- Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects 12/31/2013-3 -
CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX Tablet for Sublingual Administration XXX in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects Who Are on Lithium or Valproate A Phase IIIb, Double-Blind, Placebo-Controlled Trial of XXX in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder Depression A Double-Blind, Placebo-Controlled, Randomized Add-On Study of XXX for Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy A Phase III, Open-Label Extension Study to Assess the Safety and Tolerability of Treatment With XXX in Patients Who Have Completed Study XXX A Phase II, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of XXX in the Adjunctive Treatment of Subjects with Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment A Phase III Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX vs. Placebo in the Treatment of Psychotic Symptoms in Patients with Major Depressive Disorder with Psychotic Features A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX in Major Depressive Disorder A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of XXX on Cognitive Dysfunction in Adult Subjects with Major Depressive Disorder A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of XXX as Monotherapy Treatment in Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Therapy A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of XXX Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment 12/31/2013-4 -
CLINICAL TRIAL EXPERIENCE (continued): A Phase III,Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of XXX in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 mg XXX versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-week Open-label Extension A Phase III, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of XXX in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant A Phase IV, Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy of Two Fixed Doses (50 and 100 MG/Day) of XXX in Adult Outpatients with Major Depressive Disorder (MDD) A Phase III,, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. A Phase III, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects With Major Depressive Disorder A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of XXX in Acute Treatment of Adults With Major Depressive Disorder A Phase III, Randomized Placebo-Controlled, Double-Blind Study of XXX Flexible- Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to XXX Treatment. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of XXX in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy 12/31/2013-5 -
CLINICAL TRIAL EXPERIENCE (continued): Schizophrenia An Exploratory, Multicenter, Open-label, Flexible-dose XXX Trial in the Treatment of Adults with Early-Episode Schizophrenia A 12-Week, Randomized, Phase II, Double-blind, Parallel-group, Study of Two Dose Levels of XXX Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-Optimally Controlled Symptoms of Schizophrenia A Phase II, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Schizophrenia to Mitigate or Prevent XXX -Induced Weight Gain A Phase III, Multicenter, Extension of Study XXX to Assess the Long-term Safety and Durability of Effect of XXX in Subjects with Stable Schizophrenia A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of XXX in Subjects with Acute Exacerbation of Schizophrenia A Phase II, partial-blind, multi-center extension study to evaluate the long-term safety and health outcomes of XXX in subjects who completed Study XXX (Long-Term Safety and Efficacy of XXX in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study XXX) A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia A Randomized, Double-blind, Placebo-controlled, Parallel, 12 Week, Phase III Study of 2 Doses of XXX or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy A Phase III Multicenter 40-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of XXX as an Adjunctive Pro cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy A Phase IIb, 12 week randomized, double-blind, placebo-controlled, parallel group, multiple dose, proof-of-concept study to evaluate the effects of XXX on cognition in stable schizophrenia patients 12/31/2013-6 -
CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Non-smokers A Phase III, Randomized, Multicenter, Double-Blind, Non-inferiority Study of XXX 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of XXX on Schizophrenia Negative Symptoms A Multicenter, Open-label, Single-arm Flexible Dose (20-80 mg Twice Daily, Phase III Study of XXX in Outpatients who complete (rollover) a previous XXX Study and a Study duration of up to 2 years after US XXX Monotherapy Launch A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on XXX on Schizophrenia Negative Symptoms A Phase III, Short-term, Muticenter, Placebo-controlled, Randomized Withdrawal Study of XXX Monohydrate with DSM-IV-TR Schizophrenia A Phase III, Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with XXX Compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Community Setting in the United States A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible- Dose Study of XXX Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Incarcerated A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia A Multicenter, Double-Blind Comparison of XXX and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with XXX A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia 12/31/2013-7 -
CLINICAL TRIAL EXPERIENCE (continued): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX Evaluating Time to Relapse in Subjects With Schizoaffective Disorder A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents and A 24-Week, Flexible- Dose, Open-label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving XXX or XXX 12/31/2013-8 -
FUNDED RESEARCH ACTIVITIES: 1965-1966 G.D. Searle Research Grant for the study Pseudopregnancy Treatment of Periodic Psychiatric Illness 1971-1975 National Institute of Mental Health Grant for the project MH-20593 Short vs. Long Psychiatric Hospitalization: A Controlled Study $133,000, Supplement $ 25,484 1975-1977 Lederle Research Grant for the study XXX Treatment in Schizophrenia 1977-1978 Endo Research Grant for the study XXX vs. XXX: Double Blind Investigation of the Treatment of Acute Schizophrenia 1977-1982 National Institute of Mental Health Grant for Medical Student Psychiatric Education, $395,280 1977-1978 Vice Chancellor's Advisory Committee on Instructional Improvements Grant, UCSF, for project Effectiveness and Efficiency in Small Group Teaching with Mary Malloy, MD $ 1,400 1982-1983 National Institute of Mental Health - Biomedical Research Support Grant for the study Inpatient Family Intervention: A Controlled Study $ 15,000 1982-1983 National Institute of Mental Health Contract -to develop a Model Psychopharmacology Curriculum for Psychiatric Residency Training (with David Janowsky MD) under the auspices of the American College of Neuropsychopharmacology $ 4,290 1984-1986 National Institute of Mental Health Grant for project Inpatient Family Intervention: Evaluation of Practice, $180,000 1984-1993 National Institute of Mental Health, Cooperative Clinical Agreement Award for the project, Treatment Strategies in Schizophrenia, $863,000 1987-89 Supplement $104,000 1989-92 Competitive Renewal $688,581 1992-93 Supplement $30,000 12/31/2013-9 -
FUNDED RESEARCH ACTIVITIES (continued): 1987 XXX Research Award for the project, Delivery and Compliance to Good Medical Treatment $ 20,000 1991 XXX Grant for the study, XXX in the Treatment of the Negative Symptoms of Schizophrenia 1992-1995 National Institute of Mental Health Grant, Marital Treatment for Bipolar Disorder Patients, Co-Principal Investigator with John Clarkin, PhD, P.I. $520,000 1992 (Cornell) XXX Research Grant for the study: XXX in the & Prevention of Mania 1993 (Stanford) 1992 XXX Research Grant for the study: XXX for the Treatment of Schizophrenia and Schizoaffective Disorder 1992 (Cornell) XXX Research Grant for the study: The Safety and Efficacy of XXX in Schizophrenic Patients 1993 (Stanford) A Double-Blind, Haldol-Referenced, Placebo-Controlled Study 1993 Pharmacologic Medication Discovery & Development Project (PMDDP) Supported by XXX $10,000 1993 XXX for the Study, Treatment of Adolescent Depression with XXX 1993 XXX Grant for the study, Safety and Efficacy of XXX in the Prevention of Mania in Patients With Bipolar Disorder 1995 XXX Unrestricted grant to develop a Model Psychopharmacology Curriculum for Residents (Committee Chair) under the auspices of the American Society of Clinical Psychopharmacology 1995 XXX Research Grant for the study, XXX versus XXX in the Treatment of Schizophrenia and other Psychotic Disorders 1995 XXX Grant for the study, Dose-Response Study in the Treatment of Negative Symptoms of Schizophrenia with XXX $50,000 12/31/2013-10 -
FUNDED RESEARCH ACTIVITIES (continued): 1995 XXX Research Grant for the study, A Comparative Cost Effectiveness Study of XXX and Usual Care versus XXX and Usual Care in the Treatment of Bipolar Disorder 1996 XXX Research Grant for the study, A Multi-center, Open, Randomized Comparison of and Usual Care on Health Outcomes in Subjects with Schizophrenia and Schizoaffective Disorder 1997 XXX Research Grant for the study, A Multi-center, Randomized, Double-Blind, Placebo and Active Controlled Study of XXX in Schizophrenic and Schizoaffective Patients 1997 XXX Research Grant for the study, A Phase III Double-Blind Placebo-Controlled Study of XXX in the Treatment of Psychosis, with XXX as Active Control 1998 XXX Corporation, A Prospective, Randomized, International, Parallel-group Comparison of XXX vs. XXX in the Reduction of Suicidality in Patients with Schizophrenia or Schizoaffective Disorder Who Are at Risk for Suicide 1998 Research Grant for the investigator initiated study, XXX vs XXX for the Long-Term Treatment of Schizophrenia and Schizoaffective Disorder with Marder S. $100,000 1998 XXX, The Acute and Long-Term Efficacy of XXX in First-Episode Psychotic Disorders: A Randomized Double-Blind Comparison with XXX 1998 XXX Pharmaceuticals, A Multi-Center, Placebo Controlled Double Blind Study Comparing the Safety and Efficacy of XXX with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care. 1999 XXX, XXX vs. Placebo in the Treatment of Subjects with Schizophrenia or Schizoaffective Disorder 2009 Educational Outreach Initiative Grant $5,000 2008 XXX, A Multi-center, Double-Blind, Randomized, Active-Controlled, Study to Evaluate the Long-term Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia 12/31/2013-11 -
FUNDED RESEARCH ACTIVITIES (continued): 2008 Schizophrenia Trials Network associated with NIMH Contract XXX Comparison of Optimal Antipsychotic Treatment for Schizophrenia (COATS: A Pilot Study) XXX in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS: A Pilot Study) 2008 Keeping Up With Advances in Psychopharmacology in the New Millenium, four lectures at medical schools in Israel, supported by the Sarlo Fund and the Ingrid D. Tauber Philanthropic Fund from the Jewish Community Endowment Fund, San Francisco, June, 2008. $4,000 2008 XXX, Validation of the Reasons for Antipsychotic Discontinuation/Continuation Questionnaire (RAD-Q) and Interview (RAD-I) 2007 A Six Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral XXX in Adolescents with Schizophrenia. 2007 XXX, A Randomized, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect Of XXX Versus XXX In Patients With Schizophrenia Using the XXX 2007 American College of Neuropsychopharmacology, ACNP Public Outreach Initiative. 2007 Schizophrenia Education Day. (also supported by XXX) $5,000 2006 XXX, An Open-Label Study of Equetro in Outpatients with Aggressive Symptoms & Behavior (investigator initiated study) $125,000 2006 XXX, A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 16-week Study of XXX Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to XXX Monotherapy. 2006 XXX, A Multi-center, Double-Blind, Flexible-Dose, 6-month Trial Comparing the Efficacy and Safety of XXX in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia. 2006 CAMP (Foundation for NIH), Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to XXX vs. XXX $116,900 12/31/2013-12 -
FUNDED RESEARCH ACTIVITIES (continued): 2005 American College of Neuropsychopharmacology, ACNP Public Outreach Program $ 5,000 2005 XXX vs. XXX Double Blind. (investigator initiated Study) $120,000 2005 XXX, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of XXX in the Treatment of Schizophrenia. 2005 Co-Investigator of a XXX Grant for a project Fostering Collaboration Through Clinical Education: A Clinical Neurosciences Seminar, Clinic and Curriculum Series in Child Psychiatry and Pediatric Neurology (with Joshi SV, Chang KD and Hahn J). 2004 XXX Education Fund 2004 XXX, Comparison of Atypicals for First Episode (CAFE) $30,000 2004 XXX, The Treatment of Schizophrenia and OCD Symptomatology with XXX (investigator initiated study). $80,000 2003 XXX, Efficacy and Weight Reduction Effects of XXX in Stabilized Patients with Schizophrenia and Weight Associated with Atypical Antipsychotics (investigator initiated study with Reaven). $105,000 2003 XXX, An Open-Label Follow-Up Study of the Long-Term Safety of XXX in Patients with Psychosis. 2004 Pfizer, Zodiac International Schizophrenia Study to Compare the Cardiovascular Safety of XXX and XXX. 2003 XXX, A 12 Week Multicenter, Randomized, Double-Blind, Placebo Controlled Evaluation of XXX as Adjunctive Therapy in the Treatment of Cognitive Impairment in Patient with Schizophrenia or Schizoaffective Disorder 2001 XXX, A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Flexible Doses of XXX Versus XXX In the Treatment of Patients with Treatment-Resistant Schizophrenia 12/31/2013-13 -
FUNDED RESEARCH ACTIVITIES (continued): 2000 National Institute of Mental Health, sub-contract, Comparative Effectiveness of Antipsychotic Medications in Patients with Schizophrenia CATIE. Human Genetics Initiative $550,000 1999 Development of a Model Psychopharmacology Curriculum for Psychiatric Residents. (through the American Society of Clinical Psychopharmacology) Supported in part by XXX $15,000 EDITORIAL AND ADVISORY BOARDS: 1970-1981 Family Process 1981 Journal of Clinical Psychopharmacology 1981 Contemporary Family Therapy - An International Journal 1982 - The Journal of Family Therapy (England) 1982-1995 Board of Advisors, Dickinson College 1984-1997 The Journal of Family Psychotherapy 1984-1987 National Council of Advisors on Development and External Affairs, UCSF 1989 Progress in Neuropsychology and Biological Psychiatry 1990-1992 Advisory Board, MultiMedia Reviews in Psychiatry, Massachusetts General Hospital. 1993 Board Member, The National Mental Health Project 1993 Sertindole Advisory Board,, Neuroscience Venture, Abbott Laboratories 1995-1997 Gralnick Foundation Awards Committee 1996 CNS Science Advisory Board, Wyeth Ayerst Pharmaceutical 1997-1999 Advisory Board, Janssen Pharmaceutica and Research Foundation 1997-1999 Advisory Board, Institute for Healthcare Quality, Minneapolis 1997 Advisory Board, Zeneca Pharmaceuticals 12/31/2013-14 -
EDITORIAL AND ADVISORY BOARDS (continued): 1998 Advisory Board, Otsuka Pharmaceuticals 1999 Advisory Board, Hoechst Marion Roussel (Aventis) 1999 Advisory Board, NPSP Pharmaceuticals Bipolar Clinical Advisory Board, Boca Raton 2001, 2005 Advisory Board, Pfizer (Geodon) Pharmaceuticals 2001 Board of Directors, National Foundation for Depressive Illness, Inc. 2002, 04,05 Advisory Board, Shire Pharmaceuticals 2002, 03,04,05 Advisory Board, Bristol-Myers Squibb California Neuroscience Advisory Board 2005 - Editorial Board, The Journal of Clinical Psychiatry 2008- Editorial Board, The Physician and Sports Medicine 2009 Advisory Board, Pfizer. Anxiety Disorders AWARDS: 1953-1954 Skull & Key Award: Dickinson College. Given yearly to College's most outstanding freshman 1959 National Foundation Medical Student Fellowship, Dept. of Physical Medicine & Rehabilitation, New York Medical College (Summer) 1960 National Institute of Mental Health Research Training Grant, Dept. of Psychiatry, New York Medical College (Summer) 1961 Stephen P. Jewett Award : Dept. of Psychiatry, New York Medical College. One award given each year for proficiency in psychiatry to a fourth year medical student 1968 Army Commendation Medal: U.S. Army Hospital, Ft. Gordon, Georgia 1971-1973 Career Teacher in Psychiatry: National Institute of Mental Health, MH-12450 1974-1975 Dept. of Psychiatry Nominee for the Kaiser Award for Excellence in Teaching, and the UCSF Budget Committee Award for Special Recognition of Distinction in Teaching 12/31/2013-15 -
AWARDS (continued): 1979 American Journal of Nursing, 1979, Books of the Year Award, presented for "Psychiatric Hospital Treatment for the 1980's" 1974-1978 Consultant, Psychiatric Education Branch of the National Institute of Mental Health 1979-1980 Ad Hoc Reviewer for the Psychosocial & Biobehavioral Treatments Subcommittee of the Treatment Development and Assessment Research Review Committee, NIMH 1982 Member, Special Review Committee on Depression, ADAMHA, NIMH (July) 1987 Fulbright Research Scholar, Japan, (January through July). 1987 Research Fellowship, the Japanese National Institute of Mental Health, Itchikawa, Japan, (January through July) 1987 The American Psychiatric Association and Psychiatric Institute of America (PIA) Award for Hospital Psychiatric Research, awarded annually for research in the field of hospital psychiatric treatment. 1986 The Best Doctors in America 1990 The Seymour D. Vestermark Award, awarded annually "to recognize leadership & creativity in psychiatric education, "by the American Psychiatric Association, (given to the ACNP for a Model Curriculum in Psychopharmacology developed by a subcommittee which I co-chaired with David Janowsky, MD) 1990 Director's Award, National Institute of Mental Health 1991 The Association for Academic Psychiatry Psychiatric Education Award, Honorable Mention, awarded biannually for Innovative Educational Materials and Techniques, for the Model Curriculum in Psychopharmacology 1991 One of three recipients of Alumni Achievement Awards from New York Medical College 1991 Runner-up for The American Academy of Clinical Psychiatrists Clinical Research Award 1991-1994 MacArthur Foundation Research Network on Depression 12/31/2013-16 -
AWARDS (continued): 1993 The Van Ameringen Award in Psychiatric Rehabilitation, awarded annually by American Psychiatric Association, in recognition of outstanding and sustained contributions to field of psychiatric rehabilitation in areas of research, service and education (in 1992, I was given Honorable Mention for this same award) 1994 The Gralnick Award, given annually by the American Psychological Foundation to a researcher whose work covers the psychosocial aspects of schizophrenia with an emphasis on the early stages of the disorder 1996 Association for Academic Psychiatry Annual 1997 Education Award for outstanding contributions as an educator, both in curriculum development and in presentation 2000 Annual Outstanding Achievement Award of the Northern California Psychiatric Society (NCPS) of the APA, recognizes a member of NCPS who has made significant and exceptional contributions to the field of psychiatry. 2001 Distinguished Contribution to Family Systems Research Award. This annual AFTA award recognizes an individual for outstanding research on subjects central to the field of family therapy. 2002 Rockefeller Foundation Award for Residence at Bellagio, Italy, Summer 2002. 2003 Metzger-Conway Fellow, Clarke Center, Dickinson College, Carlisle, PA 2003 Fulbright Lecturing Award, India 2004 Excellence in Teaching Award, Stanford University School of Medicine, Stanford, CA. In recognition of contributions to the educational mission of the school. 2004 Nominee for Franklin G. Ebaugh, Jr. Award for excellence in teaching, SUSM 2005 First Annual Irma Bland Award for Excellence in Teaching Residents, given annually by the American Psychiatric Association to Departments of Psychiatry for outstanding and sustaining contributions made as a faculty. 2005 Paul Hoch Distinguished Service Award for Contributions to the College, presented by the American College of Neuropsychopharmacology 12/31/2013-17 -
AWARDS (continued): 2006 Dickinson College Distinguished Alumni Award for Professional Achievement. This yearly award names alumni who have demonstrated outstanding accomplishment, as well as strength of character, in their professional and civic lives. 2006 CINP 2006 Lundbeck Neuroscience Foundation Prize for Education in Psychiatry and Neurology, one award given every 2 years for education in psychiatry and neuroscience to an individual (or group) who has attained particularly valuable achievements in the field of postgraduate education in psychiatry and neuroscience. 2008 The American College of Psychiatrists (ACP) Distinguished Service in Psychiatry Award, one award given each year to recognize distinguished achievements and leadership in the field of psychiatry. 2008 The Association for Academic Psychiatry, Distinguished Life Fellow, given each year for mastery in a career dedicated to educational endeavors, demonstrated generativity by unselfishly guiding the next generation of academic psychiatrists, and engaged in passing on the traditions of the past to the next generation of academic psychiatrists. 2010 National Alliance on Mental Illness (NAMI) exemplatory Psychiatrist Awards ACADEMIC APPOINTMENTS: 1993- Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine 2010 Emeritus Professor 1978-1993 Professor of Psychiatry, Cornell University Medical College, New York, NY 1968-1978 School of Medicine, University of California, San Francisco (UCSF): 1968-72 Assistant Clinical Professor of Psychiatry and of Obstetrics & Gynecology 1971-73 Career Teacher in Psychiatry of the National Institute of Mental Health at Langley Porter Neuropsychiatric Institute 1972-76 Associate Clinical Professor 1976-78 Professor of Psychiatry in Residence, School of Medicine 1966-1968 Assistant Clinical Professor of Psychiatry, Medical College of Georgia 1965-1968 Instructor & Assistant Attending Psychiatrist, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University 12/31/2013-18 -
OTHER TRAINING: 1965-1966 Dept. of Research, Hillside Hospital: Seminar on Research Methods in Psychiatry, D. Klein, MD 1968-1969 J. Starkweather, PhD, Dept. of Information Systems, UCSF: An Introduction to Computer Programming PL-1 1968-1969 Dept. of Psychiatry, UCSF: Seminar on Supervision, R. Wallerstein, MD 1968-1969 Dept. of Psychiatry, UCSF: Seminars on Models in Psychiatry, J. Ruesch, MD 1969-1970 Dept. of Psychology, Langley Porter Neuropsychiatric Institute: Course on Advanced Statistics, W. Hargreaves, PhD 1971-1972 Dept. of Psychology, Langley Porter Neuropsychiatric Institute: Advanced Statistics, 226- A & B, R. Elashoff, PhD and W. Hargreaves, PhD 1971-1972 UCSF: Health Sciences Education Seminar, E. Rosinski, PhD 1972 Dept. of Anatomy, UCSF: Course on Cell Structure & Function, R. Long, PhD 1972 Dept. of Physiology, UCSF: Course, Endocrinology 101, C. Kragt, PhD 1972 Dept. of Business Administration, Philosophy of Management University of California, Berkeley Science, C. Churchman, PhD 1973 Cardiovascular Research Institute, UCSF: Group Practice in the Art of Teaching, N. Staub, MD 1978-1979 Dept. of Psychiatry, Albert Einstein College of Medicine: Administrative Psychiatry & Mental Health Planning, S. R. Kaplan, M.D. COMMITTEES: University Of California, San Francisco, School of Medicine: Department of Psychiatry Committees: 1976-1978 Administrative Planning Team, Langley Porter Institute 1976-1978 Interdisciplinary Education Committee, Dept. of Psychiatry, School of Medicine 1976-1978 Medical Student Education Committee, Dept. of Psychiatry, School of Medicine 1976 Ad Hoc Committee for Alexander Simon Award, Dept. of Psychiatry 1976 Subcommittee for Basic Curriculum, Residency Training, Dept. of Psychiatry 1975-1978 Departmental Task Force on Revision of Medical Student Curriculum, Dept. of Psychiatry 12/31/2013-19 -
COMMITTEES (continued): 1974-1978 Committee on Academic Affairs, Dept. of Psychiatry, School of Medicine, UCSF 1974-1975 Staff Affiliate Review Committee, Langley Porter Institute 1973-1978 Departmental Committee on Medical Student Education, Dept. of Psychiatry 1973-1976 Review Committee for Appointments and Promotions of Regular Faculty, Dept. of Psychiatry 1973-1978 Departmental Committee on Medical Student Education, Dept. of Psychiatry 1973 Building Committee, Langley Porter Institute 1972 Noon Conference Committee, Langley Porter Institute 1971-1973 Residency Training Committee, Langley Porter Institute 1971-1973 Residency Selection Committee, Langley Porter Institute 1970 Ad Hoc Committee on Outpatient Psychiatric Care, Dept. of Psychiatry 1969-1978 Course Committee, Sophomore Psychiatry Course, Dept. of Psychiatry 1969-1970 Ad Hoc Committee on Residency Training, Langley Porter Institute 1969 Annual Graduation and Departmental Meeting, Langley Porter Institute 1969 Course Committee, Freshman Psychiatry Course, Dept. of Psychiatry 1968-1970 Chairman, Public Health and Safety Committees, Langley Porter Institute 1968-1970 Research Committee, Clinical Research Ward, Langley Porter Institute School of Medicine Committees: 1973-1978 Curriculum Committee 1974-1978 Subcommittee on Evaluation 1974-1975 Basic Clinical Course Operations Subcommittee1974; Acting Chairman, 1975 1974 Screening and Promotions Committee 1975-1976 Search Committee, Director of Psychiatric Nursing, 1975-76 Cornell University Medical College: Department of Psychiatry Committees 1992-1993 Steering Committee 1991-1993 Residency Training Committee 1990-1993 Appointments and Promotions Committee 1990-1993 Formulary Committee 1990 Task Force on Vertical Services 1990-1993 Executive Committee 1987-1988 Executive Committee 1984-1986 Space Committee 1985-1988 Fellowship Selection Committee 1983-1988 Residency Training Committee 1981-1983 Computer Committee 1981-1983 Media Committee 1979-1983 PGY IV Education Committee 1978-1988 Inpatient Steering Committee 12/31/2013-20 -
COMMITTEES (continued): 1978-1993 Family Therapy Planning Group, 1978-1993 1978-1980 PGY II Education Committee 1978-1993 Departmental Research Committee- Chairman, 1981-83; 1983-1988 Residency Training Committee 1985-1988 Fellowship Selection Committee Stanford University School Of Medicine: Departmental Committees 1996-2005 Appointment & Promotions Chair, 1999 2005 1993-1995 Credentials Committee, Chairman 1993 - Residency Training Committee 1993-2000 Executive Committee Hospital Committees 1998-2000 UCSF/Stanford Merger - Brown & Toland Medical Group Mental Health Executive Committee 1993-2000 Inpatient Management Committee 1993-2000 Operations Improvement Committee 1993-2000 Psychiatry Business Plan Committee 1993-2000 Clinic Executive Committee Mentoring 2008-9 Jacob S. Ballon, M.D., American Psychiatric Institute for Research & Education REGIONAL AND NATIONAL PROFESSIONAL SOCIETIES: 1965-1970 American Medical Association 1965- American Psychiatric Association 1971 Fellow 1985-92 Foundations' Fund Board for Research in Psychiatry (Chair, 1985-1992) 1999 Life Fellow 1999 Member, Committee on Research on Psychiatric Treatments 2003 Sub-committee on Antipsychotic Drugs & Diabetes Mellitus Northern California Psychiatric Society (NCPS) 2004-2008 Committee on Awards 2009-2010 Counselor-at-Large 12/31/2013-21 -
REGIONAL AND NATIONAL PROFESSIONAL SOCIETIES (continued): 1970-1974 American College of Psychiatrists 1990-1990 Fellow 1996 Committee on Honorary Fellowships 1970- Society of Biological Psychiatry 1991-93 Resource Development Committee 1997 Task Force on the Future of SBP 2001 George N. Thompson Award Committee, Society of Biological Psychiatry 1973- American College of Neuropsychopharmacology 1973 & 1978 Scientific Associate Member 1980-84 Education and Training Committee, (Chair, 1982-84) 1984 Fellow 1984-1990 Co-Chair, Committee to Develop a Model Curriculum in Psychopharmacology 1987-89 Committee on Problems of Public Concern 1989-91 Task Force on Coordinating Academic Industry & Government Efforts in Psychopharmacology 1989 & '96-98 Task Force on Psychotropic Drug Prescribing Privileges for Non-physicians 1988-1992 Task Force on Scientific Misconduct 1994- Mentor, NIMH/Mead Johnson Minority Award Program 1995-1997 Finance Committee (Chair, 1997-98) 2000-2003 Constitution and Rules Committee (Chair, 2002-2004) 2005-2009 Education and Training Committee (Co-Chair, 2005-7) 2009-2010 History Committee 2010-2013 Public Information Committee 1973 Association for Academic Psychiatry, Charter Member 1978-1980 Secretary 1983 Co-Chairman and Founder, Section on Residency Training 1983-1984 Fellowship Committee 2008 Distinguished Life Fellow 1978 The Hastings Center-Institute of Society, Ethics and the Life Sciences 1978 American Family Therapy Academy 1982-1984 Board of Trustees 1985 Committee on History of AFTA 1980 American Association of Psychiatric Administrators 12/31/2013-22 -
REGIONAL AND NATIONAL PROFESSIONAL SOCIETIES (continued): 1982 Association for Clinical Psychosocial Research, Founding Member 1982-1985 Steering Committee 1988 Fellow 1984-94 Group for the Advancement of Psychiatry, Committee on the Family 1991 Program Committee 1992 Ad hoc Committee to Develop Practice Guidelines 1989 Psychiatric Research Society 1990 Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) 2002 CINP Regional Committee for North America 1992- Academia, Medicine & Psychiatric Foundation 1992 Fellow 1993- American Society of Clinical Psychopharmacology, Founding Member 1993 - Model Curriculum Committee, Chair 1995 Work Group, Interface with Government & Industry, Clinical Trials Committee 1998 - Scientific Advisory Board 2001- Treasurer 2005 Co-chair, Joint ASCP-AADPRT Curriculum Project (with David Goldberg, MD) 1993- International Society for Sports Psychiatry, Founding Member 1993 Chair, Scientific Program 1993 Executive Board 2004-2005 Chair, Nomination Committee 1997 West Coast College of Biological Psychiatry, Fellow 1998 Program Chair 1998 Pacific Rim College of Psychiatrists, Fellow VISITING PROFESSORSHIP & LECTURES: 1972 VP: Dept. of Psychiatry, School of Medicine, University of San Marcos, Lima, Peru, (August) 1) Teaching of Psychiatry to Medical Students 2) Family Therapy Today 1978-1988 Distinguished Lecturer, Lederle Pharmaceutical Co 12/31/2013-23 -
VISITING PROFESSORSHIP & LECTURES (continued): 1979 VP: Dept. of Psychiatry, College of Medicine, University of Arizona, Health Science Center, Tucson, Arizona 1980 Gary N. Spero Community Mental Health Memorial Lecture Series, "The Family Model in Inpatient and Day Hospital Settings," Maimonides Medical Center, Brooklyn 1980 VP: Dept. of Psychiatry, University of Connecticut Health Center, Farmington, Connecticut 1981 VP: Maudsley Hospital, Tavistock Clinic and Hospital for Sick Children, London 1) "The Family Model in an Inpatient Setting", Seminar on Hospital Psychiatry,Mental Health Workers, Great Britain 2) "Family Therapy and Hospitalization", Tavistock Clinic 3) "Family Research", Marlborough Hospital 4) "Family Research", Grand Rounds, Hospital for Sick Children 5) "Indications and Contraindications for Family Therapy", The Family Institute of London 1982 Keynote Address, "Guidelines for Family Therapy," as part of a continuing education course entitled "Clinical Techniques for the Practice of Family Therapy," sponsored by the Dept. of Psychiatry, Long Island Jewish- Hillside Medical Center 1982-1989 Visiting Faculty Program, Mead Johnson Pharmaceutical Co. 1983 VP: Dept. of Psychiatry, University of California, San Diego 1983 VP: Dept. of Psychiatry, College of Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 1984 Schweppes Visiting Professor, The Menninger Clinic, Topeka 1985 VP: Dept. of Psychiatry, University of Wisconsin Medical School, Madison, "The Shrinking of Hospital Psychiatry" 1985 VP, Dept. of Psychiatry, Medical University of South Carolina, Charleston 1) Grand Rounds, "Inpatient Family Intervention - A Controlled Study" 2) Inge Taylor Memorial Lecture, "Why Don't Patients Receive Appropriate Psychiatric Treatment?" 3) All Day Seminar with Psychiatry Residents, "Theory & Practice of Integrative Psychiatry" 12/31/2013-24 -
VISITING PROFESSORSHIP & LECTURES (continued): 1985 VP: Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Dept. of Psychiatry, "The Family Model: Does It Have Anything to Offer for the Treatment of Affective Disorders?" 1985 VP: Fairfield Hills Hospital, Newtown, Connecticut, "Treating the Hospitalized Patient and Their Family" 1986 VP: Dept. of Psychiatry, School of Medicine, University of Verona, Italy, Jan- Jun 1990 Visiting Lecturer Series, "Effectiveness in Psychiatric Care," New Jersey College of Medicine and Dentistry, Newark 1990 Invited Speaker, "What a Psychiatric Hospital Can and Cannot Do: A Review of Efficacy Studies." At a conference, "The Role of the Mental Hospital in the 21st Century," sponsored by the London Psychiatric Hospital, Ontario, Canada 1990 Invited Lecture, "New Wine in New Bottles: The Changing Role of Psychiatric Hospitals for Patients and Their Families," at The Sheppard Pratt National Symposium on Schizophrenia, Baltimore 1991 Academic Lecture: "New Models for the Treatment of the Chronically Mentally Ill,"Annual Meeting of the Ontario Psychiatric Association, Toronto (February) 1991 Invited Lecture: "A Survival Guide for the Family of the Borderline Patient (and Vice Versa)," New Approaches to the "Borderline Syndrome," Sixth Tokyo Institute of Psychiatry International Symposium, Tokyo, Japan (November) 1993 VP & Invited Lecture: University Institutions of Psychiatry, Geneva, School of Medicine, University of Geneva, Switzerland and Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder seen in Europe, Asia and the U.S. United States" (April) 1993 VP: Institute of Clinical Psychiatry, School of Medicine, University of Pisa, Pisa, Italy, with Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States" 1993 Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States," Dept. of Psychiatry, Second School of Medicine, Naples, Italy (April) 12/31/2013-25 -
VISITING PROFESSORSHIP & LECTURES (continued): 1993 Invited Lecture, "Effectiveness in Psychiatric Care: A Follow-up Study of the Treatment of Hospitalized Patients with Major Affective Disorder in Europe, Asia and the United States," Institute of Clinical Psychiatry and the Dept. of Psychiatry, School of Medicine, Verona, Italy. 1994 Academic Lecture: "Combining Medications with Psychosocial and Rehabilitation Strategies for the 1990's," 2nd Annual Psychopharmacology Clinical Day, Department of Psychiatry, University of Toronto, Toronto (October). 1995 Distinguished Lecturer, Professors of Psychiatry Series: New Strategies of Treatment for Axis I Disorders, 1995. 1995 VP, Department of Psychiatry, School of Medicine and Surgery, University of Bari, Italy, June. Keynote Speaker, Strategies of Intervention in Family Psychotherapy, First National Congress, Italian Society for Research and Interventions on the Family, Subsection of the Italian Psychiatric Society. 1996 Keynote Address, Combination Therapy for the Treatment of Psychosis, Third Annual STEP Symposium, Improving the Prognosis of Psychotic Disorders (Schizophrenia Treatment & Evaluation Program), University of North Carolina at Chapel Hill, June, 1996. 1996 Keynote Address, Combination Therapy for the Treatment of Axis I Disorders, 1996 Taipai Mental Health Conference, Taipai, Taiwan, December 1996. 1997 VP, Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, March 1997. 1997 Award Lecture, Through the Golden Chalkboard: Reflections on the Teaching- Learning Process in Psychiatry, 1997 Annual Meeting of the Association of Academic Psychiatry, March, 1997. 1998 VP, Department of Psychiatry & Internal Medicine, St. Francis Medical Center, Pittsburgh, PA 1998 Principal Speaker, Lone Star : Society, The Family and Individual Identity, as part of the film series of the New Orleans Museum of Art and Department of Psychiatry LSU, entitled: Lights, Camera - Analysis, New Orleans, October, 1998. 12/31/2013-26 -
VISITING PROFESSORSHIP & LECTURES (continued): 1998 Keynote Speaker, New Treatments for Schizophrenia and Other Psychoses, at the National Satellite Symposium for the Argentine Psychiatric Society, Time for Change in the Treatment of Psychosis, Buenos Aires, Argentina, November, 1998. 1998 Principal Speaker, at the National Conference organized by the Uruguayan Ministry of Health,Uruguayan Society of Psychiatry and the Psychiatric Department of the School of Medicine in the National University, Montevideo, Uruguay, November 1998: New Atypical Antipsychotics and Their Indications Combining Medication and Psychotherapy for Axis I Disorders 1999 Visiting Professor, University Hospital Utrecht, The Netherlands, Summer 1999. 1999 Plenary lectures at the Schizophrenia Symposium, Eastern Idaho Regional Medical Center, Idaho Falls, ID, June, 1999: New Strategies for the Treatment of Axis I Disorders New Treatments for Schizophrenia 1999 Plenary Lecture, New Diagnositic Methods and Treatments for Schizophrenia: Turning the Treatment Corner at the Annual Meeting of the Canadian Psychopharmacologic Association, Halifax, June, 1999 2000 Guest Lecture, The New Atypical Antipsychotics for New Indications, Annual Meeting, Korean Psychopharmacology Association, Korea, April, 2000. 2000 Visiting Professor, EPPIC Program, University of Melbourne, Melbourne, Australia, August, 2000. 2002 Invited Lecture, Novel Antipsychotics: What We ve Learned; What We Need to Know. CME course on Novel Antipsychotics, Case Western Reserve University School of Medicine, Cleveland, September, 2002. 2004 Visiting Professor, Family Studies Unit, National Institute Mental Health and Health Series (NIMHANS), Bangalore, India Combining Medication and Psychotherapy The New Model of Inpatient Psychiatry 2004 Inaugural Lecture, Gary N. Spero Memorial Lectureship, Schizophrenia and Psychosis: New Data, New (Combined) Treatments & New Controversies. Department of Psychiatry, Weill Medical College of Cornell University, New York, March, 2004. 12/31/2013-27 -
VISITING PROFESSORSHIP & LECTURES (continued): 2004 Visiting Professor, School of Medicine, University of Iowa Combining Medication and Psychotherapy for Axis I Disorders Schizophrenia: New Data and New Controversies 2005 At the Indonesian Society for Biological Psychiatry, Psychopharmacology and Sleep Medicine, Jakarta, Indonesia, February, 2005. Educational Symposia, The Teaching of Psychopharmacology: Circa 2005 Opening Plenary Lecture: Developing a Curriculum in Psychopharmacology 2005 Lecture: Developing a Curriculum in Psychopharmacology. Teaching Psychopharmacology: Substance, Methods, Science. Pre-Meeting: American Association of Directors of Psychiatric Residency Training, Tucson, AZ, March, 2005 2005 Invited Lecture, Collaboration With Big Pharma, as part of the Stanford Summer Research Institute, entitled Careers in Geriatric Psychopharmacology. Stanford, CA, July, 2005 2006 Invited Lecture. Using a Psychopharmacology Curriculum to Improve Training. Dept of Psychiatry, Cape Town Medical School, Cape Town, South Africa, April, 2006 2006 Invited Lecture: CATIE Trial Results. At the Annual ECNP (European College of Neuropsychopharmacology) Meeting, Paris, September 2006. 2007 Invited Lecture: Clinical Antipsychotic Trials in Intervention Effectiveness. Oregon Psychiatric Association, Lake Oswego-Portland, OR, March 2007. Panel Discussion on CATIE trial, with W Hoffman, M Reaves, D Ruthven 2007 Invited Lecture: Teaching of Psychopharmacology Worldwide, consultant for the Lundbeck Institute, Copenhagen, Denmark, March 2007. 2007 Invited Participant: Joint Committee on Long-Term Management of Schizophrenia, Houston, April and October, 2007, Chaired by William Carpenter and John Newcomer. 2008 Visiting Professor and Invited Lectures: The Teaching of Psychopharmacology: 2008, Department of Psychiatry, Sackler School of Medicine, Tel Aviv University and Sheba Medical Center, Tel Aviv, Israel Department of Psychiatry, Rappoport Faculty of Medicine Institute of Technology, Technion, Haifa, Israel 12/31/2013-28 -